Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…
News
Sickle Cell disease (SCD) is one of the most prevalent genetic diseases worldwide. It is a type of anemia characterized by the hemoglobin variant hemoglobin S (HbS), which causes rigidity in red cells and “sickling.” This sickling changes their shape, resulting in a number of life-long complications for patients with…
Today, four million Americans live with a chronic autoimmune disease known as Sjögren’s Syndrome (SS). The condition causes mucous membranes and other glands to function improperly, triggering a series of complications in several organs. According to a recent study, one of these complications is the onset of pulmonary…
Adriano Tonelli and colleagues at the Cleveland Clinic in Ohio have found a number of electrocardiography (ECG) variables that evolve between diagnosis and death in individuals with pulmonary arterial hypertension (PAH) that warrant further investigation. Currently, the medical community does not recommend an ECG for PAH diagnosis. Fifty…
Among the fives types of PH, Pulmonary Arterial Hypertension (PAH) is recognized as a serious unmet medical need in terms of viable treatments, due to the progressive and life-threatening characteristics of the disease.  PAH patients experience symptoms where blood pressure in the pulmonary arteries is significantly heightened due to vasoconstriction, frequently…
